Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease with a high disease burden that requires long-term management. One herbal ingredient with potential for development as a complementary therapy is the butterfly pea flower (Clitoria ternatea), which contains polyphenols, flavonoids, and anthocyanins with biological activities related to the regulation of glucose metabolism. This study aims to analyze the therapeutic potential and pharmacological mechanisms of C. ternatea extract as an antidiabetic agent in T2DM. The study employed a narrative review design with a mixed-evidence synthesis. A literature search was conducted via Google Scholar and PubMed for publications from 2016 to 2026. Primary articles, including in vitro, in vivo, and human studies, were selected based on inclusion and exclusion criteria, with the selection process adhering to the PRISMA 2020 guidelines. Of the 16,504 articles identified, 11 primary studies met the criteria and were included in the synthesis, comprising 2 human studies, 5 in vivo studies, and 4 in vitro studies. The results indicate that C. ternatea extract has the potential to inhibit α-amylase and/or α-glucosidase activity, reduce glucose release or levels, enhance antioxidant capacity, suppress certain inflammatory mediators, and modulate insulin-related parameters. However, the magnitude of these effects varies depending on the type of solvent, dose, formulation, study model, and outcome parameters. Evidence in humans remains limited, is acute in nature, has not yet involved patients with type 2 diabetes mellitus (T2DM), and does not yet provide data on HbA1c or long-term safety. Thus, C. ternatea has the potential to be developed as a herbal-based complementary therapy for T2DM, but the available evidence is not yet sufficient to support its use as a substitute for standard therapy.